Medical Greens (SKTO) Signs Management Agreement With Medical Cannabis Growers With Aggregate of Over 12,000 Square Feet of I...
Today : Wednesday 8 January 2014
Medical Greens (SKTO) Signs Management Agreement With Medical Cannabis Growers With Aggregate of Over 12,000 Square Feet of Indoor Cultivation Space in California
LOS ANGELES, CA--(Marketwired - Jan 8, 2014) - SK3 Group, Inc's (OTC Pink: SKTO) subsidiary Medical Greens ("the Company") announces it has signed a new management contract with medical marijuana growers that have an aggregate of over 12,000 square feet of indoor cultivation in California, in full compliance with state medical marijuana laws and guidelines.
These managed medical cannabis growers are currently in the process of switching to cultivating non-psychoactive strains of medical marijuana that are high in the non-psychoactive cannabinoid Cannabidiol (commonly abbreviated CBD). These non-psychoactive high-CBD strains are primarily used for medicinal purposes.
This agreement provides an exclusive supply of high-CBD raw materials that is a key ingredient in various products that the Company has licensed to its Wholesale Managed Collectives.
Mr. Artemus Mayor, President of the Company, said, "We believe that the market for non-psychoactive medical marijuana products is many times the size of the market for the highly psychoactive medical marijuana products that are currently available. With the increasing acceptance of medical marijuana around the US, the number of medical marijuana patients will grow significantly, increasing demand for the non-psychoactive cannabinoid and CBD products that our licensees produce."
FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.
About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact
SK3 Group, Inc.
investors@medicalgreens.com
Investor Relations
Today : Wednesday 8 January 2014
Medical Greens (SKTO) Signs Management Agreement With Medical Cannabis Growers With Aggregate of Over 12,000 Square Feet of Indoor Cultivation Space in California
LOS ANGELES, CA--(Marketwired - Jan 8, 2014) - SK3 Group, Inc's (OTC Pink: SKTO) subsidiary Medical Greens ("the Company") announces it has signed a new management contract with medical marijuana growers that have an aggregate of over 12,000 square feet of indoor cultivation in California, in full compliance with state medical marijuana laws and guidelines.
These managed medical cannabis growers are currently in the process of switching to cultivating non-psychoactive strains of medical marijuana that are high in the non-psychoactive cannabinoid Cannabidiol (commonly abbreviated CBD). These non-psychoactive high-CBD strains are primarily used for medicinal purposes.
This agreement provides an exclusive supply of high-CBD raw materials that is a key ingredient in various products that the Company has licensed to its Wholesale Managed Collectives.
Mr. Artemus Mayor, President of the Company, said, "We believe that the market for non-psychoactive medical marijuana products is many times the size of the market for the highly psychoactive medical marijuana products that are currently available. With the increasing acceptance of medical marijuana around the US, the number of medical marijuana patients will grow significantly, increasing demand for the non-psychoactive cannabinoid and CBD products that our licensees produce."
FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.
About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact
SK3 Group, Inc.
investors@medicalgreens.com
Investor Relations
